Efficacy and Safety of Upadacitinib in Moderate-to-Severe IBD: A Systematic Review of RCTs in Biologic-Na&#195;&#175;ve and Biologic-Experienced Populations

Jyseleca (filgotinib) - Gilead

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

Rinvoq (upadacitinib) - AbbVie

Zeposia (ozanimod) - BMS

Pradeep Rajbhandari; MD; MS; MPH

Aug 29, 2026